Phase 2 N=4 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
Charcot Marie Tooth Disease
Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=323 Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
Charcot-Marie-Tooth Disease Type 1A
Primary: Overall Neuropathy Limitation Scale (ONLS) Total Score — 3.33; 3.05; 3.23; 3.25 Scores on the ONLS — p=0.008
Phase 2 N=80 Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
Charcot-Marie-Tooth Disease · Hereditary Neuropathy With Liability to Pressure Palsies · Genetic Disorders
Primary: Safety and Tolerability of PXT3003 — 21; 21; 19; 19 Participants
Phase 2 N=12 The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
CMT
Primary: Safety of Intramuscular (IM) Injections of Engensis in Participants — 1; 1; 1; 1 Participants
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
N/A N=88 Non-invasive CTS Device Clinical Trial
Carpal Tunnel Syndrome
Primary: BCTQ SSS at 8 Weeks vs Baseline — 2.16; 2.32; -0.62; -0.64 score on a scale
Phase 3 N=190 A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)
Autism
Primary: Primary Outcome Measurements to Determine Efficacy of Treatment With CM-AT Versus Placebo for Changes in the Aberrant Behavior Checklist Subscale for Irritability /…
Phase 3 N=4,786 Cardiovascular Inflammation Reduction Trial
Cardiovascular Disease
Primary: Number of Subjects With Major Adverse Cardiovascular Events — 170; 167 participants — p=0.91
Phase 3 N=161 HEALEY ALS Platform Trial - Regimen C CNM-Au8
Amyotrophic Lateral Sclerosis
Primary: Disease Progression as Assessed by the ALSFRS-R Total Score — -1.01; -1.03 ALSFRS-R total score points per month
Phase 2 N=42 Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
Myotonic Dystrophy
Primary: Mean Change From Baseline in Ambulation Using the 6 Minute Walk Distance — 17.44; 7.25 Meters
Phase 2 N=14 MC-5A for Chemotherapy Induced Peripheral Neuropathy
Neuropathy, Paraneoplastic
Primary: Change in Mechanical Visual Analog Scale (mVAS) Using Quantitative Sensory Pain Testing (QSPT) — 5.14; -2.00; 1.25; 6.76 Millimeters
N/A N=30 Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy
Cardiomyopathy
Primary: Change in Left Ventricular Ejection Fraction — 10.6 percentage of LVEF
Phase 1 N=32 Effects Multimodal Mind and Body Approach for MCI
Mild Cognitive Impairment
Primary: Retention — 11; 15 Participants
N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
N/A N=36 Spinal Cord Injury Program in Exercise
Spinal Cord Injuries
Primary: Physical Activity Level at Week 8 — 383; 297 Minutes per week
Phase 2 N=56 CMC (Carpometacarpal) OA (Osteoarthritis) Thumb Splint Study
Osteoarthritis
Primary: Hand Function — 5.54; 2.69 units on a scale
N/A N=32 Therapeutic Effects of Constraint-Induced Movement Therapy on Young Children With Cerebral Palsy
Cerebral Palsy Spastic Hemiplegic
Primary: Change From Baseline Pediatric Motor Activity Log (PMAL) Score at Post Test — 0.83; 0.00; 0.50; -0.05 score on a scale
N/A N=31 Thumb Osteoarthritis: A Cross-Sectional Study of Mechanisms
Carpometacarpal Osteoarthritis
Primary: Australian Canadian OA Hand Index (AUSCAN) — 3.3; 1.3; 2.0; 1.6 score on a scale
Phase 2 N=33 Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
Macular Telangiectasia Type 2
Primary: Frequency of Ocular and/or Non-ocular Treatment Emergent Adverse Events — 26; 26; 6; 13 Participants
N/A N=13 Safety and Efficacy of a Novel Carpal Tunnel Tissue Manipulation Device in Treating Carpal Tunnel Syndrome
Carpal Tunnel Syndrome
Primary: Change in SSS of the BCTQ at 28 Days vs Baseline — 0.59; 0.93; .00 point decrease in SSS
N/A N=1,002 The Maintaining Musculoskeletal Health Study
Widespread Chronic Pain
Primary: Development of Chronic Widespread Pain Assessed by Questionnaire — 69; 77 Participants
Phase 1 N=12 TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
Early Phase 1 N=6 CIMT and taVNS for Hemiplegia in Infants
Infant Development · Hemiplegia · Constraint Induced Movement Therapy
Primary: CIMT Fidelity — 3.76 score on a scale
N/A N=8 Postural Stability in Cervical Spinal Myelopathy
Cervical Spondylotic Myelopathy
Primary: Virtual Environment TBI System (VETS) Assessment of Static Posturography — 11; 13.0; 48.4; 19.1 Square Centimeters
N/A N=57 DTM (TM) Spinal Cord Stimulation (SCS) Study
Chronic Pain
Primary: Visual Analog Scale (VAS) — -3.9 Centimeter
Phase 2 N=131 A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.70; -1.81 score on a scale
N/A N=16,789 Chronic Migraine Epidemiology and Outcomes Study
Migraine Disorders
Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants
Phase 3 N=127 A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: ACR20 Responses at Week 24 — 11; 54 participants
N/A N=57 TelemEdiciNe-bAsed Cognitive TherapY for Migraines
Migraine Headache
Primary: Number of Headache Days at 3 Months — 18.17; 19.19; 16.47; 18.26 headache days — p=0.61
Phase 4 N=128 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
Chronic Myelogenous Leukemia in Chronic Phase
Primary: Number of Participants With Confirmed Complete Molecular Response (CMR) — 34 Participants